Safety study of GR2303 in healthy adults
This trial tests a new drug called GR2303 to see if it is safe and how the body processes it. It is for healthy adults who have not used similar drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult.
- You must sign a consent form agreeing to join the study.
- You cannot have any serious ongoing medical condition.
- You cannot have used a drug that targets TNF-like cytokine 1A before.
- You cannot have a history of cancer.
- You must test negative for hepatitis B, hepatitis C, and HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called GR2301 to see if it is safe in healthy people. Volunteers will help researchers understand any side effects before the drug is given to patients with a disease.
This is an early-stage study testing a new medicine called GR2301 given as multiple injections. Researchers want to see how safe it is and how the body handles it in healthy volunteers with no serious medical conditions.
This is an early-stage safety study testing a new experimental drug called REGN22044 in people with no serious health conditions. Researchers want to understand how safe the drug is, how well people tolerate it, and how the body processes it.
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
This trial tests a new combination drug (AG2304) compared to taking two separate drugs together. It's for healthy adults to see how the body handles the drugs and check for safety.
This trial tests an investigational drug in healthy people to see how safe it is and how the body processes it. It may help researchers decide if the drug should be studied further for a specific condition.
Hear when a new Health Adult Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.